Breast cancer · 35 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
FEC-THP (Docetaxel) Variant #03 | ERBB2 | R 86 349 | 21d | — | — | 17 | R 515 045 PFS proxy | 1 |
EC-THP (Docetaxel) Variant #01 | ERBB2 | R 86 268 | 21d | — | — | 17 | R 514 721 PFS proxy | 1 |
ddEC-THP (Docetaxel) Variant #01 | ERBB2 | R 86 268 | 21d | — | — | 17 | R 514 721 PFS proxy | 1 |
AC-THP (Docetaxel) Variant #01 | ERBB2 | R 84 072 | 21d | — | — | 17 | R 505 937 PFS proxy | 1 |
FAC-THP (Docetaxel) Variant #01 | ERBB2 | R 84 040 | 21d | — | — | 17 | R 505 096 PFS proxy | 1 |
FEC-THP (Paclitaxel) Variant #01 | ERBB2 | R 82 991 | 21d | — | — | 17 | R 514 273 PFS proxy | 1 |
ddEC-THP (Paclitaxel) Variant #01 | ERBB2 | R 82 910 | 21d | — | — | 17 | R 513 950 PFS proxy | 1 |
EC-THP (Paclitaxel) Variant #01 | ERBB2 | R 82 910 | 21d | — | — | 17 | R 513 950 PFS proxy | 1 |
ddAC-THP (Docetaxel) Variant #01 | ERBB2 | R 81 799 | 21d | — | — | 17 | R 506 586 PFS proxy | 1 |
ddAC-THP (Paclitaxel) Variant #01 | ERBB2 | R 80 714 | 21d | — | — | 17 | R 505 165 PFS proxy | 1 |
AC-THP (Paclitaxel) Variant #01 | ERBB2 | R 80 714 | 21d | — | — | 17 | R 505 165 PFS proxy | 1 |
FAC-THP (Paclitaxel) Variant #01 | ERBB2 | R 80 682 | 21d | — | — | 17 | R 504 325 PFS proxy | 1 |
TH-FEC (Docetaxel) Variant #01 | ERBB2 | R 32 698 | 21d | — | — | ~3 | ~R 55 919 indirect | — |
VH-FEC Variant #01 | ERBB2 | R 31 150 | 21d | — | — | ~3 | ~R 51 272 indirect | — |
ddAC-ddTH (Paclitaxel) Variant #01 | ERBB2 | R 25 509 | 14d | — | — | ~45 | ~R 256 680 indirect | — |
FEC-TH (Docetaxel) Variant #01 | ERBB2 | R 21 635 | 21d | — | — | 17 | R 104 300 PFS proxy | 1 |
AC-TH (Docetaxel) Variant #01 | ERBB2 | R 19 998 | 21d | — | — | 17 | R 100 135 PFS proxy | 2 |
FAC-TH (Docetaxel) Variant #01 | ERBB2 | R 19 966 | 21d | — | — | 17 | R 99 294 PFS proxy | 1 |
EC-TH (Docetaxel) Variant #01 | ERBB2 | R 19 922 | 21d | — | — | 17 | R 109 568 PFS proxy | 1 |
ddEC-TH (Docetaxel) Variant #01 | ERBB2 | R 19 922 | 21d | — | — | 17 | R 109 568 PFS proxy | 1 |
FEC-TH (Paclitaxel) Variant #01 | ERBB2 | R 18 917 | 21d | — | — | 17 | R 105 449 PFS proxy | 1 |
EC-TH (Paclitaxel) Variant #01 | ERBB2 | R 18 836 | 21d | — | — | 17 | R 108 148 PFS proxy | 1 |
ddEC-TH (Paclitaxel) Variant #01 | ERBB2 | R 18 836 | 21d | — | — | 17 | R 108 148 PFS proxy | 1 |
ddFEC-ddTH (Docetaxel) Variant #01 | ERBB2 | R 18 420 | 21d | — | — | ~12 | ~R 92 424 indirect | — |
ddAC-TH (Docetaxel) Variant #01 | ERBB2 | R 17 725 | 21d | — | — | 17 | R 100 784 PFS proxy | 1 |
AC-TH (Paclitaxel) Variant #01 | ERBB2 | R 16 640 | 21d | — | — | 17 | R 99 363 PFS proxy | 3 |
ddAC-TH (Paclitaxel) Variant #01 | ERBB2 | R 16 640 | 21d | — | — | 17 | R 99 363 PFS proxy | 1 |
FAC-TH (Paclitaxel) Variant #01 | ERBB2 | R 16 608 | 21d | — | — | 17 | R 98 523 PFS proxy | 1 |
AC-H Variant #01 | ERBB2 | R 10 143 | 21d | — | — | ~51 | ~R 246 766 indirect | — |
D-FEC Variant #01 | ERBB2 | R 5 432 | 21d | — | — | 3 | R 16 295 PFS proxy | 1 |
TH-FEC (Docetaxel, SC Trastuzumab) Variant #01 Partial | ERBB2 | R 4 965 | 21d | — | — | ~3 | ~R 14 895 indirect | — |
V-FEC Variant #01 | ERBB2 | R 3 947 | 21d | — | — | ~3 | ~R 8 639 indirect | — |
AC-D Variant #01 | ERBB2 | R 3 692 | 21d | — | — | 4 | R 14 767 PFS proxy | 2 |
AC-T Variant #01 | ERBB2 | R 2 077 | 21d | — | — | 4 | R 8 309 PFS proxy | 2 |
FAC-MV Variant #01 | — | R 2 065 | 28d | — | — | ~6 | ~R 9 173 indirect | — |
35 of 35 regimens shown